Klotho Neurosciences Acquires Greenland Mines for Strategic Resource Control Klotho Neurosciences has acquired Greenland Mines Corp., securing a significant palladium and gold resource valued at $68 billion in a vital trade corridor.

Klotho Neurosciences Acquires Greenland Mines for Strategic Resource Control #United_States #Charlotte #Klotho_Neurosciences #Greenland_Mines #Skaergaard_Project

Klotho Neurosciences Launches Innovative Aging Diagnostics Using AI and Epigenetics Klotho Neurosciences is developing groundbreaking diagnostics integrating AI and epigenetics to understand biological aging and longevity.

Klotho Neurosciences Launches Innovative Aging Diagnostics Using AI and Epigenetics #USA #New_York #AI_Diagnostics #Klotho_Neurosciences #Klotho_Clock

Klotho Neurosciences Expands Patent Portfolio in Australia for Klotho Protein Applications and Use Klotho Neurosciences has announced the acceptance of multiple patent claims in Australia, focusing on the innovative uses of the Klotho protein for treating neuromuscular diseases.

Klotho Neurosciences Expands Patent Portfolio in Australia for Klotho Protein Applications and Use #Australia #Not_specified #Klotho_Neurosciences #Klotho_Protein

Klotho Neurosciences Set to Showcase Innovations in Biotech at 2026 Event Klotho Neurosciences is preparing for a significant presentation at the 2026 Biotech Showcase, highlighting groundbreaking advancements in biogenetics aimed at combatting neurodegenerative diseases.

Klotho Neurosciences Set to Showcase Innovations in Biotech at 2026 Event #United_States #San_Francisco #R&D #Klotho_Neurosciences #biotech_show

Klotho Neurosciences CEO Participates in Longevity Biotech 2025 Event in Boston Klotho Neurosciences, Inc. confirms its participation in Longevity Biotech 2025 in Boston, fostering discussions on aging therapies with investors and peers.

Klotho Neurosciences CEO Participates in Longevity Biotech 2025 Event in Boston #United_States #Boston #Klotho_Neurosciences #Longevity_Biotech #Dr._Joseph_Sinkule

Klotho Neurosciences Concludes Its Agreement with Turn Biotechnologies Klotho Neurosciences has officially announced the expiration of their Letter of Intent with Turn Biotechnologies, refocusing on its anti-aging research.

Klotho Neurosciences Concludes Its Agreement with Turn Biotechnologies #USA #New_York #Anti-Aging #Turn_Biotechnologies #Klotho_Neurosciences

Klotho Neurosciences Targets Growth Through Strategic Acquisition of Turn Biotechnologies' Assets Klotho Neurosciences has signed a Letter of Intent to acquire key assets from Turn Biotechnologies, bolstered by a significant pharmaceutical partnership.

Klotho Neurosciences Targets Growth Through Strategic Acquisition of Turn Biotechnologies' Assets #United_States #New_York #Turn_Biotechnologies #Klotho_Neurosciences #longevity_therapies

Klotho Neurosciences CEO to Attend Inaugural Conference on Neurodegenerative Therapies Dr. Joseph Sinkule of Klotho Neurosciences will be attending the inaugural Klotho Conference in Irvine, California, showcasing innovative therapies for neurodegeneration.

Klotho Neurosciences CEO to Attend Inaugural Conference on Neurodegenerative Therapies #USA #Irvine,_California #Klotho_Neurosciences #Joseph_Sinkule #Klotho_Conference

Klotho Neurosciences Holds Inaugural Conference on Neurodegenerative Therapies Klotho Neurosciences, Inc.'s CEO, Dr. Joseph Sinkule, will participate in the company's inaugural conference on neurodegenerative therapies.

Klotho Neurosciences Holds Inaugural Conference on Neurodegenerative Therapies #Klotho_Neurosciences #neurodegenerative_therapies #CEO_Dr._Joseph_Sinkule

CEO of Klotho Neurosciences to Attend Inaugural Conference in California Klotho Neurosciences announces its CEO will meet investors at the inaugural conference discussing therapies for neurodegenerative diseases.

CEO of Klotho Neurosciences to Attend Inaugural Conference in California #USA #Irvine #Neurodegenerative_Diseases #Klotho_Neurosciences #Joseph_Sinkule

Klotho Neurosciences CEO to Lead Discussions at Historic Neurodegenerative Conference Klotho Neurosciences' CEO, Dr. Joseph Sinkule, will attend the inaugural Klotho Conference in California on September 15-16, focusing on groundbreaking neurodegenerative therapies.

Klotho Neurosciences CEO to Lead Discussions at Historic Neurodegenerative Conference #USA #Irvine #Klotho_Neurosciences #Joseph_Sinkule #NASDAQ:KLTO

Klotho Neurosciences CEO to Participate in Historic Conference on Neurodegenerative Therapies Dr. Joseph Sinkule, CEO of Klotho Neurosciences, will attend the first Klotho Conference to discuss innovative therapies for neurodegenerative diseases.

Klotho Neurosciences CEO to Participate in Historic Conference on Neurodegenerative Therapies #USA #Irvine #Klotho_Neurosciences #Klotho_gene_therapy #Joseph_Sinkule

Klotho Neurosciences, Inc. Launches Production of KLTO-202 Gene Therapy with AAVnerGene Klotho Neurosciences has begun manufacturing its KLTO-202 gene therapy using advanced AAVnerGene technology that promises efficiency and safety in production.

Klotho Neurosciences, Inc. Launches Production of KLTO-202 Gene Therapy with AAVnerGene #United_States #New_York #Klotho_Neurosciences #KLTO-202 #AAVnerGene

Klotho Neurosciences Set to Broaden Research Focus to Enhance Longevity and Wellness Klotho Neurosciences, Inc. plans to diversify its development efforts to include technologies that support brain health and longevity, beyond neurology.

Klotho Neurosciences Set to Broaden Research Focus to Enhance Longevity and Wellness #United_States #New_York #gene_therapy #Anti-Aging #Klotho_Neurosciences

Klotho Neurosciences Reaffirms Compliance with NASDAQ Listing Standards Klotho Neurosciences successfully meets NASDAQ's minimum bid and equity requirements, solidifying its market position as a leader in gene therapy for neurodegenerative diseases.

Klotho Neurosciences Reaffirms Compliance with NASDAQ Listing Standards #None #gene_therapy #Nasdaq_Compliance #Klotho_Neurosciences

Klotho Neurosciences Secures FDA Orphan Drug Designation for ALS Treatment with KLTO-202 Klotho Neurosciences has received FDA Orphan Drug Designation for KLTO-202, a pivotal step towards treating ALS, a rare and fatal neurodegenerative condition.

Klotho Neurosciences Secures FDA Orphan Drug Designation for ALS Treatment with KLTO-202 #ALS #Klotho_Neurosciences #KLTO-202

Klotho Neurosciences Advances Gene Therapy for ALS Treatment with New Manufacturing Initiatives Klotho Neurosciences is progressing with the manufacturing of KLTO-202, a gene therapy aimed at treating ALS, marking a significant advancement in neurological medicine.

Klotho Neurosciences Advances Gene Therapy for ALS Treatment with New Manufacturing Initiatives #USA #New_York #ALS_Treatment #Klotho_Neurosciences #KLTO-202

Klotho Neurosciences Partners with Okinawa Research Center to Study Aging Gene in Centenarians Klotho Neurosciences is collaborating with Okinawa Research Center to research the Klotho gene in centenarians, aiming to unlock the secrets to longevity and healthy aging.

Klotho Neurosciences Partners with Okinawa Research Center to Study Aging Gene in Centenarians #USA #New_York #Klotho_Neurosciences #Okinawa_Research #Longevity_Science

Klotho Neurosciences Terminates Share Agreement with SkyBell, Enhances Focus on Longevity Research Klotho Neurosciences has mutually ended its share exchange agreement with SkyBell Technologies, allowing a refocused strategy on therapeutic advancements and longevity research.

Klotho Neurosciences Terminates Share Agreement with SkyBell, Enhances Focus on Longevity Research #United_States #New_York #Therapeutics #Klotho_Neurosciences #SkyBell_Technologies

Klotho Neurosciences Secures Over $11 Million Funding, Eliminating All Debt and Meeting Nasdaq Equity Requirements Klotho Neurosciences has successfully raised over $11 million, cleared all debt, and is now compliant with Nasdaq's stockholders' equity criteria.

Klotho Neurosciences Secures Over $11 Million Funding, Eliminating All Debt and Meeting Nasdaq Equity Requirements #United_States #New_York #financing #Klotho_Neurosciences #KLTO